What Are the Challenges in Developing Smac Mimetics?
Despite their potential, there are several challenges in developing Smac mimetics for clinical use. One major challenge is achieving selectivity; while targeting IAPs in cancer cells is desirable, off-target effects on normal cells can lead to toxicity. Additionally, the development of resistance to Smac mimetics is another concern, necessitating combination therapies to ensure sustained efficacy. Finally, understanding the complex biology of IAPs and their interactions with other cellular pathways remains a significant hurdle.
